CHAPEL HILL, N.C., Aug. 6, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the NIAID workshop Bridging the Gap – Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases on August 9 to 10 in Rockville, MD. Dr. Fernandes will present how Cempra is working to overcome bottlenecks during the clinical development of one of its clinical candidates, solithromycin. The workshop is planned by the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, with the goal of helping to advance new therapeutics for infectious diseases through the product development pipeline. About Cempra, Inc. Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com. Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.Investor and Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.email@example.com Andreas MarathovouniotisRusso Partners, LLC(212) 845-4235 Andreas.firstname.lastname@example.org SOURCE Cempra Pharmaceuticals Inc.